Pembrolizumab for Squamous Cell Carcinoma User Reviews
Brand names: Keytruda
Pembrolizumab has an average rating of 6.3 out of 10 from a total of 3 reviews for the treatment of Squamous Cell Carcinoma. 67% of reviewers reported a positive experience, while 33% reported a negative experience.
- Bill
- Taken for less than 1 month
- August 27, 2023
Keytruda (pembrolizumab) "Initially no adverse effects. After 4-5 days, extreme tiredness, feeling weak, especially in my hands. After a week or so, I developed a low-grade fever up to 102 and more of a cough. I called the treatment center, and they said this is not a Keytruda side effect. I took a COVID test, and it was negative. I assume I just have a cold or flu? I have not had a cold or flu of any kind for at least 8-9 years. The swellings in my neck are going down. This was my first injection."
- Amni
- Taken for 6 months to 1 year
- August 3, 2023
Keytruda (pembrolizumab) "Have not noticed any side effects so far. Been on Keytruda for 6 months. Originally in combination with Carboplatin/Pax and for the last 2 months only Keytruda. Couldn't get it approved to start sooner. My hope is it will keep the remaining tumors in check and maybe even kill them (Stage 4 anal/vaginal)"
Frequently asked questions
- Pembrolizumab vs. nivolumab: How do they compare?
- How are Inlyta and Keytruda used in kidney cancer?
- What type of cancer is pembrolizumab used for?
- How does pembrolizumab affect the immune system?
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about pembrolizumab
- Check interactions
- Compare alternatives
- Reviews (227)
- Side effects
- Dosage information
- During pregnancy
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Keytruda (pembrolizumab) "We found out my Dad had squamous cell lung cancer stage 4 in June, he tried radiation which didn't work, doctors didn't suggest chemo but suggested immunotherapy Keytruda instead. I had really high hopes for immunotherapy after reading and seeing good things about it on abc news claiming it could be the "cure". Me and my family definitely had high hopes, and we all thought it would be safer than chemo, less side effects. August 24th 2022 Wed is when they gave keytruda to him through iv. I saw him the next day and he seemed fine in the hospital despite his other health problems and his legs being paralyzed from the tumor. Sunday I called the hospital to check on how he was doing. Nurses said he wasn't doing good... somehow his oxygen was depleting in his body and he wasn't responding to their oxygen. I rushed to the hospital Aug 28th Sun and saw my Dad for the last time, held his hand while I watched him breathe his last breath unconscious. He was starved of oxygen because of this..."